Targeting intracellular calcium cycling in catecholaminergic polymorphic ventricular tachycardia: A theoretical investigation

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 301, Issue 4, 2011, Pages

  Sung, Ruey J ^a,c   Lo, Chu Pin ^b   Hsiao, Pi Yin ^a   Tien, Hui Chun ^b  

^a NATIONAL CENTRAL UNIVERSITY   (Taiwan)

^b PROVIDENCE UNIVERSITY   (Taiwan)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Computational modeling; Delayed afterdepolarizations; Store overload induced Ca 2+ release; Triggered activity

Indexed keywords

CALCIUM CHANNEL; CALSEQUESTRIN; RYANODINE RECEPTOR 2; SODIUM CALCIUM EXCHANGE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; BETA ADRENERGIC STIMULATION; CALCIUM TRANSPORT; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; CONTROLLED STUDY; DELAYED AFTERDEPOLARIZATION; DEPOLARIZATION; GENE MUTATION; HEART ARRHYTHMIA; HEART MUSCLE CELL; HEART PACING; INTRACELLULAR CALCIUM CYCLING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOPLASMIC RETICULUM;

ADRENERGIC BETA-AGONISTS; ALGORITHMS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CALCIUM; CALCIUM-TRANSPORTING ATPASES; CATECHOLAMINES; ELECTRIC STIMULATION; GAP JUNCTIONS; GUINEA PIGS; ION CHANNELS; MEMBRANE POTENTIALS; MICE; MUTATION; MYOCYTES, CARDIAC; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM; SPECIES SPECIFICITY; TACHYCARDIA, VENTRICULAR;

EID: 80053256790     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00696.2010     Document Type: Article

References (40)

1. Antzelevitch C, Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol 23: 259-277, 1994.
2. Cerrone M, Colombi B, Santoro M, di Barletta MR, Scelsi M, Villani L, Napolitano C, Priori SG. Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. Circ Res 96: e77-e82, 2005.
3. Cerrone M, Noujaim SF, Tolkacheva EG, Talkachou A, O'Connell R, Berenfeld O, Anumonwo J, Pandit SV, Vikstrom K, Napolitano C, Priori SG, Jalife J. Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia. Circ Res 101: 1039-1048, 2007.
4. Clancy CE, Zhu ZI, Rudy Y. Pharmacogenetics and anti-arrhythmic drug therapy: a theoretical investigation. Am J Physiol Heart Circ Physiol 292: H66-H75, 2007.
5. ++ pump inhibitors on release channels of intracellular stores. J Pharmacol Exp Ther 285: 739-745, 1998.
6. 2+ handling and increased mortality. J Am Coll Cardiol 57: 469-479, 2011.
7. Endoh M. Force-frequency relationship in intact mammalian ventricular myocardium: physiological and pathophysiological relevance. Eur J Pharmacol 500: 73-86, 2004.
8. 2+ channel and its role in myocyte electrophysiology: a theoretical investigation. Biophys J 92: 1522-1543, 2007.
9. Faber GM, Rudy Y. Calsequestrin mutation and catecholaminergic polymorphic ventricular tachycardia: a simulation study of cellular mechanism. Cardiovasc Res 75: 79-88, 2007.
10. 2+ sensitivity of the ryanodine receptor mutant RyR2R4496C underlies catecholaminergic polymorphic ventricular tachycardia. Circ Res 104: 201-209, 2009.
11. Gima K, Rudy Y. Ionic current basis of electrocardiographic waveforms: a model study. Circ Res 90: 889-896, 2002.
12. Herron TJ, Milstein M, Anumonwo J, Priori SG, Jalife J. Purkinje cell calcium dysregulation is the cellular mechanism that underlies catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 7: 1122-1128, 2010.
13. 2+ spark mass. J Mol Cell Cardiol 48: 293-301, 2010.
14. Iyer V, Armoundas AA. Unraveling the mechanisms of catecholaminergic polymorphic ventricular tachycardia. Conf Proc IEEE Eng Med Biol Soc Suppl: 6761-6764, 2006.
15. 2+ release (SOICR). Proc Natl Acad Sci USA 101: 13062-13067, 2004.
16. Kashimura T, Briston SJ, Trafford AW, Napolitano C, Priori SG, Venetucci LA. In the RyR2(R4496C) mouse model of CPVT, β-adrenergic stimulation induces Ca waves by increasing SR Ca content and not by decreasing the threshold for Ca waves. Circ Res 107: 1483-1489, 2010.
17. Katra RP, Laurita KR. Cellular mechanism of calcium-mediated triggered activity in the heart. Circ Res 96: 535-542, 2005.
18. Katz G, Khoury A, Kurtzwald E, Hochhauser E, Porat E, Shainberg A, Seidman JG, Seidman CE, Lorber A, Eldar M, Arad M. Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin- mutant mice. Heart Rhythm 7: 1676-1682, 2010.
19. Kleber AG, Rudy Y. Basic mechanisms of cardiac impulse propagation and associated arrhythmias. Physiol Rev 84: 431-488, 2004.
20. Koivumaki JT, Takalo J, Korhonen T, Tavi P, Weckstrom M. Modelling sarcoplasmic reticulum calcium ATPase and its regulation in cardiac myocytes. Philos Transact A Math Phys Eng Sci 367: 2181-2202, 2009.
21. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 91: 1512-1519, 1995.
22. Liu N, Colombi B, Memmi M, Zissimopoulos S, Rizzi N, Negri S, Imbriani M, Napolitano C, Lai FA, Priori SG. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. Circ Res 99: 292-298, 2006.
23. Liu N, Priori SG. Disruption of calcium homeostasis and arrhythmogenesis induced by mutations in the cardiac ryanodine receptor and calsequestrin. Cardiovasc Res 77: 293-301, 2008.
24. R4496C+/- mice with catecholaminergic polymorphic ventricular tachycardia. J Mol Cell Cardiol 50: 214-222, 2011.
25. Livshitz L, Rudy Y. Uniqueness and stability of action potential models during rest, pacing, and conduction using problem-solving environment. Biophs J 97: 1265-1276, 2009.
26. Lyon AR, Bannister ML, Collins T, Pearce E, Sepehripour AH, Dubb SS, Garcia E, O'Gara P, Liang L, Kohlbrenner E, Hajjar RJ, Peters NS, Poole-Wilson PA, Macleod KT, Harding SE. SERCA2a gene transfer decreases sarcoplasmic reticulum calcium leak and reduces ventricular arrhythmias in a model of chronic heart failure. Circulation 4: 362-372, 2011.
27. Rohr S. Role of gap junctions in the propagation of the cardiac action potential. Cardiovasc Res 62: 309-322, 2004.
28. Rosso R, Kalman JM, Rogowski O, Diamant S, Birger A, Biner S, Belhassen B, Viskin S. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 4: 1149-1154, 2007.
29. Rudy Y. Multiple interactions determine cellular electrical processes in the multicellular tissue. Cardiovasc Res 51: 1-3, 2001.
30. 2+ overload induces arrhythmogenic events in mouse cardimyocytes with a human CPVT mutation. Cardiovasc Res 87: 50-59, 2010.
31. Silva JR, Pan H, Wu D, Nekouzadeh A, Decker KF, Cui J, Baker NA, Sept D, Rudy Y. A multiscale model linking ion-channel molecular dynamics and electrostatics to the cardiac action potential. Proc Natl Acad Sci USA 106: 11102-11106, 2009.
32. 2+ wave development in ventricular myocytes. Cardiovasc Res 86: 63-71, 2010.
33. Sung RJ, Wu SN, Wu JS, Chang HD, Luo CH. Electrophysiological mechanisms of ventricular arrhythmias in relation to Andersen-Tawil syndrome under conditions of reduced IK1: a simulation study. Am J Physiol Heart Circ Physiol 291: H2597-H2605, 2006.
34. Sung RJ, Wu YH, Lai NH, Teng CH, Luo CH, Tien HC, Lo CP, Wu SN. β-Adrenergic modulation of arrhythmogenesis and identification of targeted sites of antiarrhythmic therapy in Timothy (LQT8) syndrome: a theoretical study. Am J Physiol Heart Circ Physiol 298: H33-H44, 2010.
35. Terentyev D, Kubalova Z, Valle G, Nori A, Vedamoorthyrao S, Terentyeva R, Viatchenko-Karpinski S, Bers DM, Williams SC, Volpe P, Gyorke S. Modulation of SR Ca release by luminal Ca and calsequestrin in cardiac myocytes: effects of CASQ2 mutations linked to sudden cardiac death. Biophys J 95: 2037-2048, 2008.
36. van der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A, Shimizu W, Sumitomo N, Fish FA, Bhuiyan ZA, Willems AR, van der Veen MJ, Watanabe H, Laborderie J, Haïssaguerre M, Knollmann BC, Wilde AAM. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol 57: 2244-2254, 2011.
37. Venetucci LA, Trafford AW, O'Neill SC, Eisner DA. The sarcoplasmic reticulum and arrhythmogenic calcium release. Cardiovasc Res 77: 285-292, 2008.
38. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, Duff HJ, Roden DM, Wilde AA, Knollmann BC. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 15: 380-383, 2009.
39. Wilde AA, Bhuiyan ZA, Crotti L, Facchini M, De Ferrari GM, Paul T, Ferrandi C, Koolbergen DR, Odero A, Schwartz PJ. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med 358: 2024-2029, 2008.
40. Xu X, Yano M, Uchinoumi H, Hino A, Suetomi T, Ono M, Tateishi H, Oda T, Okuda S, Doi M, Kobayashi S, Yamamoto T, Ikeda Y, Ikemoto N, Matsuzaki M. Defective calmodulin binding to the cardiac ryanodine receptor plays a key role in CPVT-associated channel dysfunction. Biochem Biophys Res Commun 394: 660-666, 2010.